BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE

被引:0
|
作者
KITAGAWA, M
OKABE, T
OGINO, H
MATSUMOTO, H
SUZUKITAKAHASHI, I
KOKUBO, T
HIGASHI, H
SAITOH, S
TAYA, Y
YASUDA, H
OHBA, Y
NISHIMURA, S
TANAKA, N
OKUYAMA, A
机构
[1] MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN
[2] NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN
[3] KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.
引用
收藏
页码:2425 / 2432
页数:8
相关论文
共 50 条
  • [1] THE CHARACTERIZATION OF HUMAN CDC2 KINASE AND CDK2
    YASUDA, H
    KAMIJO, M
    OHBA, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1993, 113 (12): : 829 - 846
  • [2] Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells
    Yamamoto, H
    Monden, T
    Miyoshi, H
    Izawa, H
    Ikeda, K
    Tsujie, M
    Ohnishi, T
    Sekimoto, M
    Tomita, N
    Monden, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (02) : 233 - 239
  • [3] INHIBITION OF CELL-CYCLE OSCILLATION OF DNA-REPLICATION BY A SELECTIVE INHIBITOR OF THE CDC2 KINASE FAMILY, BUTYROLACTONE-I, IN XENOPUS EGG EXTRACTS
    SOMEYA, A
    TANAKA, N
    OKUYAMA, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 198 (02) : 536 - 545
  • [4] Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines
    Nishio, K
    Ishida, T
    Arioka, H
    Kurokawa, H
    Fukuoka, K
    Nomoto, T
    Fukumoto, H
    Yokote, H
    Saijo, N
    ANTICANCER RESEARCH, 1996, 16 (6B) : 3387 - 3395
  • [5] Structure based drug design: Selective inhibitors of CDC2 and CDK2
    Brooks, FE
    Lum, R
    Mackman, R
    Joly, A
    Shiffman, D
    FASEB JOURNAL, 1997, 11 (09): : A1220 - A1220
  • [6] A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2
    Park, SG
    Cheon, JY
    Lee, YH
    Park, JS
    Lee, KY
    Lee, CH
    Lee, SK
    MOLECULES AND CELLS, 1996, 6 (06) : 679 - 683
  • [7] Differential regulation of Cdc2 and Cdk2 by RINGO and Cyclins
    Karaiskou, A
    Perez, LH
    Ferby, I
    Ozon, R
    Jessus, C
    Nebreda, AR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) : 36028 - 36034
  • [8] Cdk2 and Cdk4 cooperatively control the expression of Cdc2
    Cyril Berthet
    Philipp Kaldis
    Cell Division, 1
  • [9] CYCLIN-DEPENDENT KINASE-2 (CDK2) IN THE MURINE CDC2 KINASE TS MUTANT
    YASUDA, H
    NAKATA, T
    KAMIJO, M
    HONDA, R
    NAKAMURA, M
    NINOMIYATSUJI, J
    YAMASHITA, M
    NAGAHAMA, Y
    OHBA, Y
    SOMATIC CELL AND MOLECULAR GENETICS, 1992, 18 (05) : 403 - 408
  • [10] GENOMIC ORGANIZATION OF MURINE HOMOLOGS OF CDC2 AND CDK2
    JUN, D
    PARK, HK
    LEE, YH
    KIM, Y
    NAGEL, J
    NORDIN, A
    FASEB JOURNAL, 1995, 9 (03): : A233 - A233